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Abstract
Background: Recent studies focused on modulating factors of paraoxonase-1 (PON1) activity. In some studies the
association between pro-inflammatory markers and PON1 activity was examined, but so far no population-based
investigations on this issue have been conducted. The present study investigated the relationships between the
pro-inflammatory markers tumor necrosis factor (TNF)-α, leptin, interleukin (IL)-6, and high-sensitive C-reactive
protein (hs-CRP) and paraoxonase and arylesterase, two hydrolytic activities of PON1, in the population-based
Bavarian Food Consumption Survey II.
Methods: Based on 504 participants (217 men, 287 women), the relationship between the pro-inflammatory
markers and the outcomes paraoxonase and arylesterase activities were investigated using multivariable linear
models.
Results: Circulating plasma levels of leptin (P-value < 0.0001), hs-CRP (P-value = 0.031) and IL-6 (P-value = 0.045)
were significantly non-linearly associated with arylesterase activity. Leptin levels were also significantly associated
with paraoxonase activity (P-value = 0.024) independently from confounding factors, including high-density
lipoprotein (HDL) cholesterol. With increasing levels of these inflammatory parameters, arylesterase and
paraoxonase activities increased; however, at higher levels (> 75th percentile) the activities reached a plateau or
even decreased somewhat. After Bonferroni-Holm correction, only leptin remained non-linearly but significantly
associated with arylesterase activity (adjusted overall P-value < 0.0001). Neither age nor sex nor obesity modified the
associations. No association was found between TNF-α and paraoxonase or arylesterase activity.
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Conclusions: The present findings suggest that in persons with very high levels of inflammation, PON1 activity may
be impaired, a fact that might subsequently be accompanied by a higher risk for cardiometabolic diseases. Whether
or not the measurement of PON1 activity in combination with a lipid profile and certain inflammatory markers
could improve the prediction of cardiometabolic diseases in middle-aged individuals from the general population
should be evaluated in clinical studies.
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Background
Nowadays one of the greatest challenges of medicine is
the increasing prevalence of cardiometabolic diseases,
such as type 2 diabetes, non-alcoholic fatty liver disease,
and metabolic syndrome [1]. This increase is mainly due
to overnutrition in combination with physical inactivity
and sedentarism [2]. In the past two decades, the patho-
physiological mechanisms that contribute to the manifest-
ation of cardiometabolic diseases, which are commonly
associated with premature death, have been the subject of
numerous research activities [3, 4]. A wealth of evidence
highlights chronic low-grade inflammation and oxidative
stress as common underlying mechanisms. A large num-
ber of adipokines [5] which are mainly secreted from adi-
pose tissue, seem to be involved in the regulation of
energy expenditure, carbohydrate and lipid metabolism,
hunger/satiety, immune response, inflammation and oxi-
dative stress [6, 7]. Evidence suggests that the mechanism
by which inflammation and oxidative stress are involved
in the development of cardiometabolic diseases is multi-
factorial. However, it seems that changes in high-density
lipoprotein (HDL) structure and function during inflam-
mation could play a role [8]. HDL cholesterol is known to
correlate inversely with atherosclerotic diseases. Its pro-
tective effect is due to its ability to enhance cholesterol ef-
flux from peripheral cells back to the liver. However, a
number of additional protective properties of HDL choles-
terol have recently been discovered, such as anti-
inflammatory and antioxidant functions [9]. One of the
anti-atherogenic effects of HDL cholesterol is due to
paraoxonase-1 (PON1), a glycoprotein that is synthesized
primarily by the liver and is mostly bound on HDL in the
blood [10]. PON1 is endowed with three hydrolytic activ-
ities, namely paraoxonase activity, arylesterase activity,
and lactonase activity [10]. Recent research activities thus
focus on modulating factors of PON1 activity [11–13]. A
few prior studies investigated whether adipokines had an
effect on PON1 activity, but these studies were mainly
based on patient groups with a certain disease [12, 14, 15],
on females or males only [11, 13], or on small sample sizes
[16]. So far, data in a large population-based study includ-
ing healthy individuals with mainly low values of inflam-
matory markers are still scarce. The present study can
contribute to closing this research gap by investigating the
association between the pro-inflammatory factors tumor
necrosis factor (TNF)-α, leptin, interleukin (IL)-6, and
high-sensitive C-reactive protein (hs-CRP) and paraoxo-
nase activity as well as arylesterase activity in a sample of
the general adult population in Germany. Furthermore, it
was examined whether the associations were modified by
obesity, sex or age.
Methods
The Bavarian Food Consumption Survey II (BVSII) is a
representative cross-sectional study of the German-
speaking population of Bavaria, Germany, and was con-
ducted in 2002–2003. The examination included the
conduct of a personal interview, the assessment of three
24-h dietary recalls by telephone, the collection of blood
and the measurement of height, weight and waist cir-
cumference. Altogether 1050 randomly selected individ-
uals aged 13 to 80 years participated in the personal
interview, i.e. 71% of the eligible individuals participated
in the study. Altogether, 879 completed the baseline
interview and at least one dietary recall and were thus
invited to a study center for blood collection and an-
thropometric measurements; 568 participants (65%)
completed the requested examinations. Detailed infor-
mation on the BVSII has been described in detail else-
where [17–19]. Written informed consent was provided
by all study participants and the study was approved by
the ethics committee of the Bavarian Medical Associ-
ation on June 19th, 2002 (Ethik-Kommission Nr. 02111).
The investigations were carried out in accordance with
the Declaration of Helsinki. After exclusion of 64 partici-
pants with missing values in any of the relevant vari-
ables, the present study included 504 BVSII participants
for analysis.
Laboratory methods
Venous serum and EDTA blood samples were obtained
in a non-fasting state. After processing and aliquoting,
the samples were stored at − 80 °C until analysis. Paraox-
onase and arylesterase activities were spectrophotomet-
rically measured in serum samples at a temperature of
25 °C and a pH of 8 [20]. Using paraoxon as the sub-
strate, the enzymatic activity of PON1 was determined;
the reaction was recorded at 405 nm. One unit of para-
oxonase activity equals 1 nmol of P-nitrophenol formed/
min/ml. Arylesterase activity was determined at 270 nm
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with phenylacetate as the substrate and one unit of ary-
lesterase activity equals 1 μmol of phenylacetate hydro-
lysed/min per ml [20].
The inflammation markers hs-CRP, IL-6, and TNF-α
were measured in plasma using commercial ELISAs
(Biosource, Brussels, Belgium). The methods have been
described in detail elsewhere [21]. All assays had an
intra-assay coefficient of variation (CV) < 7%, and an
interassay CV < 9% [21]. The polypeptide leptin was
measured using a radioimmunoassay [22].
Statistical analysis
All associations between the exposures TNF-α, leptin,
IL-6 and hs-CRP and the outcomes paraoxonase and
arylesterase activities were investigated using linear re-
gression models. The models were adjusted for age, alco-
hol consumption, HDL cholesterol and either waist
circumference or BMI (in sensitivity analyses) as con-
tinuous variables and sex, physical activity, socioeco-
nomic and smoking status as categorical variables.
Furthermore, it was investigated whether obesity, sex or
age modified the associations by applying formal tests
for interaction based on a 5% significance level. For
comparison, overall and sex-specific results were
presented.
To improve the model fit and capture the linearity as-
sumption between continuous covariates and the out-
come, restricted cubic splines were used, if necessary.
Thus, in case of non-linearity, the number of quantile-
based knots was determined with respect to the adjusted
R2, Bayesian information criterion (BIC) and likelihood
ratio tests against the model with only linear terms.
Multicollinearity was assessed calculating the variance
inflation factor and homoscedasticity was ensured by the
Breusch-Pagan test as well as visual approval of residual
plots. Due to high leverage quantified by Cook’s D, one
influential observation had to be removed from models
with IL-6 as exposure. Finally a sensitivity analysis was
done by excluding HDL cholesterol from the models.
Resulting P-values as well as confidence intervals were
corrected by the Bonferroni-Holm method. The analyses
were conducted using the software R (version 4.0.3.).
Results
Baseline characteristics
Characteristics and circulating biomarker concentrations
of the total study sample and also for men and women
separately are shown in Table 1. The participants had a
median age of 46 years (interquartile range (IQR) 37.8;
62.0) and their median body mass index (BMI) was 25.9
kg/m2 (IQR 23.0;29.0). They had a median waist circum-
ference of 92.5 cm (IQR 83.0;103.1) and a median HDL
cholesterol of 45.8 mg/dl (IQR 41.2;51.8). A proportion
of 10.1% belonged to the highest socioeconomic status.
Furthermore, the proportions of former and current
smokers were 23.4 and 24.0%, respectively; 45.6% re-
ported being physically inactive. Median alcohol con-
sumption was 7.5 g/day (IQR 0.4; 21.0). The median
value of paraoxonase activity was 89.3 U/ml (IQR 61.1;
154.8) and of arylesterase activity was 163.7 U/ml (IQR
139.1; 189.5).
Altogether, 43.1% of the study participants were males.
In comparison to women, levels of TNF-α and IL-6 were
significantly higher in men, while in women leptin levels
were significantly higher than in men. Furthermore,
male participants consumed significantly higher amounts
of alcohol, were more often current smokers, and had a
higher median BMI and waist circumference in compari-
son to women. Women had significantly higher HDL
values and a significantly higher median arylesterase ac-
tivity than men.
There were no notable correlations between inflamma-
tory markers and paraoxonase and arylesterase activities
(Spearman’s correlations: − 0.04 ≤ r ≤ 0.14).
Regression analyses
The multivariable linear regressions were adjusted for
sex (only for the total sample), age, waist circumference,
physical activity, alcohol consumption, socioeconomic
status, HDL cholesterol, and smoking status. They re-
vealed consistently linear, non-significant positive (for
the independent inflammatory markers TNFα and IL-6)
or negative (for CRP) associations with the outcome par-
aoxonase activity. These relationships were found in the
total sample and also in the sex-specific analyses. The
results for the linear associations are shown in Table 2
(total sample) and in Table 3 (sex-specific analyses).
Leptin values were non-linearly associated with para-
oxonase activity. Therefore, restricted cubic splines
modelling with 3 knots was applied. The association was
significant in the total sample (P-value for overall associ-
ation 0.024), but after correction for multiple testing the
significance was lost (adjusted P-value for overall associ-
ation 0.142). Similar results were found in the sex-
specific analyses. The results for the non-linear associa-
tions are displayed in Fig. 1 (total sample) and Fig. 2
(sex-specific analyses).
Multivariable linear regression models also showed a
linear but non-significant positive association between
TNF-α and arylesterase activity in the total sample
(Table 2) as well as in the sex-specific analyses (Table 3).
Leptin as well as CRP and IL-6 were non-linearly asso-
ciated with arylesterase activity in the total sample (Fig.
1). In restricted cubic spline models, the associations be-
tween CRP and arylesterase activity as well as IL-6 and
arylesterase activity were significant (overall P-value
0.031 and 0.045, respectively), but significance did not
persist after correction for multiple testing. In contrast,
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leptin was non-linearly but significantly associated with
arylesterase activity, even after Bonferroni-Holm correc-
tion (overall P-value < 0.0001; adjusted overall P-value <
0.0001). In the sex-specific analyses these findings could
be largely confirmed (Fig. 2).
Interaction with sex, age, and obesity
In all analyses we tested for interactions between bio-
markers and BMI, waist circumference, sex and age to
explore whether obesity, sex or age modifies the
appropriate biomarker values (data not shown). All of
the tested interactions were not significant, indicating
that neither obesity (P-value > 0.27) nor age (P-value >
0.06) nor sex (P-value > 0.19) modify the associations.
Sensitivity analyses
In the sensitivity analyses, we adjusted the models for
the aforementioned confounders but not for HDL chol-
esterol, and obtained quite similar results to those from
the main analyses (data not shown). Furthermore, when
Table 2 Results of the linear regression models on the relationship between plasma inflammation markers and serum paraoxonase
or arylesterase activities (total sample)
Outcome Exposure β (fully adjusted)a 95% CI corrected P-value P-value corrected
Paraoxonase activity TNF-α 0.400 −0.407; 1.207 0.266 0.532
Hs-CRP −0.199 −1.206; 0.807 0.697 0.697
IL-6 0.655 −0.367; 1.678 0.124 0.373
Arylesterase Activity TNF-α 0.450 −0.156; 1.056 0.063 0.253
aadjusted for age, sex, waist circumference, alcohol consumption, HDL cholesterol, physical activity, socioeconomic status, and smoking status
Table 1 Characteristics and circulating biomarker concentrations and activities in BVSII participants; median (IQR) or absolute
numbers n (%)
Overall (n = 504) Men (n = 217) Women (n = 287) P
Paraoxonase activity (U/ml) 89.3 (61.1; 154.8) 86.7 (60.4; 156.0) 96.5 (63.6; 154.0) 0.481
Arylesterase activity (U/ml) 163.7 (139.1; 189.5) 159.3 (138.8; 184.9) 168.3 (139.8; 194.4) 0.043
TNFα(pg/ml) 11.2 (8.8; 14.5) 12.0 (9.4; 15.3) 10.9 (8.4; 13.7) 0.004
Leptin (pg/ml) 9.3 (5.3; 16.8) 5.5 (3.5; 8.8) 13.1 (8.5; 22.7) < 0.0001
Hs-Crp (ng/ml) 1.6 (0.8; 3.7) 1.6 (0.8; 3.4) 1.59 (0.8; 3.9) 0.807
IL-6 (pg/ml) 1.4 (0.95; 2.4) 1.5 (1.1; 2.7) 1.3 (0.9; 2.2) 0.006
Age 46.0 (37.8; 62.0) 53.0 (38.0; 64.0) 44.0 (37.0; 59.0) 0.002
Alcohol consumption (g/day) 7.5 (0.4; 21.0) 19.2 (5.1; 34.5) 3.8 (0.2; 12.2) < 0.0001
HDL cholesterol (mg/dl) 45.8 (41.2; 51.8) 43.7 (39.9; 48.4) 48.2 (42.8; 53.5) < 0.0001
BMI (kg/m2) 25.9 (23.0; 29.0) 26.6 (24.1; 29.4) 25.1 (22.3; 28.7) < 0.0001
Waist circumference (cm) 92.5 (83.0; 103.1) 100.0 (92.5; 107.0) 86.0 (78.0; 97.3) < 0.0001
Socioeconomic status 0.089
1 (lowest) 66 (13.1) 23 (10.6) 43 (15.0)
2 120 (23.8) 54 (24.9) 66 (23.0)
3 158 (31.3) 68 (31.3) 90 (31.4)
4 109 (21.6) 42 (19.4) 67 (23.3)
5 (highest) 51 (10.1) 30 (13.8) 21 (7.3)
Physical activity (hours per week) 0.351
0 230 (45.6) 95 (43.8) 135 (47.0)
0.1 to 3.9 144 (28.6) 59 (27.2) 85 (29.6)
> =4 130 (25.8) 63 (29.0) 67 (23.3)
Smoking status < 0.0001
never 265 (52.6) 89 (41.0) 176 (61.3)
former 118 (23.4) 64 (29.5) 54 (18.8)
current 121 (24.0) 64 (29.5) 57 (19.9)
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Table 3 Results of the linear regression models on the relationship between plasma inflammation markers and serum paraoxonase
or arylesterase activities in the sex-specific subgroup analyses
Outcome Exposure β (fully adjusted)a 95% CI P-value P-value corrected
MEN
Paraoxonase Activity TNF-α 0.624 −0.338; 1.586 0.203 1.000
Hs-CRP −0.177 −1.553; 1.198 0.800 1.000
IL-6 1.844 0.504; 3.183 0.007 0.078
Arylesterase Activity TNF-α 0.207 −0.442; 0.857 0.531 1.000
WOMEN
Paraoxonase Activity TNF-α 0.192 −0.812; 1.197 0.707 1.000
Hs-CRP −0.177 −1.605; 1.252 0.808 1.000
IL-6 −0.092 −1.154; 0.971 0.865 1.000
Arylesterase Activity TNF-α 0.707 0.029; 1.385 0.041 0.410
aadjusted for age, waist circumference, alcohol consumption, HDL cholesterol, physical activity, socioeconomic status, and smoking status
Fig. 1 Non-linear associations between leptin, hs-CRP and IL-6 levels and paraoxonase as well as arylesterase activities, respectively (total sample).
Models were adjusted for age, sex, waist circumference, alcohol consumption, HDL cholesterol, physical activity, socioeconomic status, and
smoking status
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adjusting for BMI instead of waist circumference in the
multivariable analysis, comparable results could be gen-
erated (data not shown).
Discussion
In this population-based study, circulating levels of lep-
tin, hs-CRP and IL-6 were significantly related to aryles-
terase activity, which is one of the hydrolytic activities of
PON1, an enzyme bound on HDL cholesterol [23]. Nei-
ther age nor sex nor obesity modified the associations.
The relationship between leptin and arylesterase activity
remained significant even after adjusting for multiple
testing. No associations between TNF-α and paraoxo-
nase or arylesterase activity were found.
The significant relationship between pro-inflammatory
markers and arylesterase activity but not paraoxonase
activity could be due to the fact that some prevalent
PON1 genetic polymorphisms have almost no influence
on arylesterase activity. In addition, arylesterase activity
shows low interindividual variability. This is why
arylesterase activity is regarded as a better surrogate of
PON1 concentration than paraoxonase activity [24].
Studies examining the association between different
inflammatory markers and PON1 activities in in vitro
models have been performed previously. However, stud-
ies in humans are still scarce, and the existing results are
inconsistent. The population-based PolSenior project,
which included 3154 individuals aged 65 and higher, did
investigate the association of PON1 arylestease activity
with a number of factors including sex, age, several age-
dependent diseases, and some serum lipids and inflam-
matory markers [25]. It could be shown that there was a
link between lower PON1 activity and higher levels of
hs-CRP and IL-6. In contrast to previous studies the
present population-based study for the first time in-
cluded middle-aged adults to examine whether there is
an association between inflammatory markers and para-
oxonase and arylesterase activities.
The cytokine IL-6 has pro- and anti-inflammatory
properties [26]; it is a primary determinant of the
Fig. 2 Non-linear associations in the sex-specific subgroup analyses between leptin, hs-CRP and IL-6 levels and paraoxonase as well as
arylesterase activities, respectively. Models were adjusted for age, waist circumference, alcohol consumption, HDL cholesterol, physical activity,
socioeconomic status, and smoking status
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hepatic production of CRP [27]. Levels of IL-6 are very
low under normal conditions, but these levels can raise
extensively as a consequence of an inflammatory re-
sponse [28].
Experimental studies have shown that IL-6 and TNF-α
up- and down-regulate PON1 gene expression, which
suggests that inflammatory markers might have an im-
pact on PON1 activity [29, 30]. However, whether there
is a relationship between the blood levels of these in-
flammatory markers and PON1 levels/activity could not
be answered by these studies. In the present investiga-
tion, a significant association between IL-6 (but not
TNF-α) and arylesterase activities was found. Due to a
lack of population-based studies on this issue, compar-
ability with other findings is difficult.
In the BVSII also a significant association between hs-
CRP, the major acute phase reactant during acute inflam-
mation [31], and arylesterase activity was observed. Some
prior studies including certain groups of patients have in-
vestigated whether high CRP levels are related to PON1
activity [14, 32, 33]. In a study by Dullaart et al. including
patients with type 2 diabetes mellitus low PON1 activity
was associated with higher CRP levels independent of
plasma adipokines, obesity and plasma lipids [14]. In an-
other study including persons with diabetes, persons with
coronary heart disease but no diabetes, and control sub-
jects, high CRP levels were related to low PON1 activity,
suggesting that there is a mechanistic link between inflam-
mation and the development of atherosclerosis [32]. Fur-
thermore, a recent study including 285 hospitalized
patients, 115 of whom received a surgical intervention, re-
ported a decreased PON1 activity and an increased acute
phase response in patients after surgery due to post-
surgical metabolic alterations [33].
In the present study, the link between plasma leptin
levels and arylesterase activity was not modified by obes-
ity. In prior animal studies, adverse effects of leptin on
PON1 activity could be shown [34, 35], and rats treated
with leptin exhibited a decrease in PON1 activity [36].
However, human studies investigating such correlations
at the systemic level came to different results [12, 37–
40]. In a study by Bajnok et al. [12], associations of leptin
with PON1 were investigated in 74 overweight-obese
participants in comparison to 24 normal-weight subjects;
it was reported that leptin inversely correlated with
PON1, but the association was not independent from
confounders [12]. Similar results were obtained in a
study including obese children [38], obese females [39],
and morbidly obese patients after bariatric surgery [40].
Yet contrary to these results, in a study including pa-
tients undergoing hemodialysis [37] no significant in-
verse association between leptin and PON1 was found.
In contrast to these studies conducted in certain patient
groups with rather higher (pathological) inflammatory
values, the present study included mainly healthy sub-
jects in a non-inflammatory state and in some cases per-
sons with inflammatory values in a pathological stage. It
is possible that the findings between inflammatory
markers and PON1 activity in this study are due to dif-
ferences between the study samples with regard to state
of inflammation.
The antioxidant enzyme PON1 is mainly synthesized
and secreted by the liver, and in the circulation bound
to HDL transported to several tissues [41]. By binding to
cell membranes, PON1 protects lipids against peroxida-
tion [42] and prevents low-density lipoprotein oxidation
[43], which is a major cause of inflammation and is in-
volved in the initiation of inflammatory diseases such as
atherosclerosis, diabetes, and cancer [44].
Thus, in the normal state, HDL has, among other fea-
tures, antioxidative and anti-inflammatory properties.
However, it can be hypothesized that in a state of sys-
temic inflammation, HDL may undergo changes and
lose its protective properties, possibly due to the loss of
activity of the antioxidant enzyme PON1 [45]. The
present study found associations between some inflam-
matory markers, which are correlated to cardiometabolic
disease development, and arylesterase activity. The asso-
ciations in the present study were generally positive until
the 75th percentile and reached a plateau regarding
PON1 activity with higher values of the inflammatory
parameters. Interestingly, contrary to other studies
reporting a relationship between inflammatory markers
and PON1 in certain subgroups [12, 38], obesity, sex
and age do not seem to modify the associations in this
population-based sample. This is possibly due to the fact
that the present study included healthy participants with
mainly non-pathological levels of inflammatory markers.
Further studies are needed to unravel whether and how
systemic inflammation is involved in the conversion of
HDL from a protective to a dysfunctional form [46–48].
Furthermore, while the activities of paraoxonase and
arylesterase are now often subjects of research, the level
of knowledge on lactonase activity in connection with
inflammation is scarce [49]. Recent studies in certain pa-
tient groups, such as cancer patients or in patients after
surgery found lower arylesterase and lactonase activity
in states of chronic inflammation [50, 51]. The link be-
tween PON1 lactonase activity and inflammation should
be evaluated in further studies.
Study strength and limitations
The strengths of the present study are the large
population-based sample and the availability of compre-
hensive data. A limitation of the study is its cross-
sectional design, which cannot show causal relationships.
Furthermore, the present study sample consisted of
European Caucasians in a certain age-range; therefore it
Meisinger et al. Lipids in Health and Disease           (2021) 20:81 Page 7 of 10
is not representative for other ethnicities or age-groups.
Also, blood samples were collected in a non-fasting
state. Prior studies could show that meal intake has an
influence on the plasma concentration of inflammatory
markers [52]. This fact may have influenced the findings
of this study. Finally, no measurement of lactonase activ-
ity was available in the present study because knowledge
on lactonase activity of PON1 was rare in 2004 and
established later [53].
Conclusions
The present study showed that plasma IL-6, hs-CRP,
and leptin were non-linearly associated with arylesterase
activity. Leptin levels were also significantly associated
with paraoxonase activity; with increasing levels of in-
flammation, the activity of arylesterase and paraoxonase
increased. However, with higher levels (> 75th percent-
ile) of inflammatory parameters, the activities reached a
plateau or even decreased somewhat, suggesting that
such high levels of inflammation may lead to impaired
enzyme activity and subsequently to dysfunctional HDL
in middle-aged individuals from the general population.
This finding could be clinically relevant because it sug-
gests that this group of people may have a higher risk
for cardiometabolic diseases. Whether or not a measure-
ment of PON1 activity in combination with the lipid
profile and certain inflammatory markers could improve
the prediction of cardiometabolic diseases should be
evaluated in clinical studies.
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